Axel Mescheder

NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA.

SSP Technology A/S designs, develops, and optimizes wind turbine blades. Its product range embraces wind turbine blade technology, mould manufacture, and blade development. The company was founded by Rune Schytt-Nielsen and Flemming Sørensen in 2001 and is headquartered in Stenstrup, Denmark.

DSM Venturing BV (DSM Venturing) is the venture capital arm of Royal DSM NV in the Netherlands founded in 2001. DSM Venturing BV is headquartered in Geleen.

ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands.

Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom.

ACS Biomarker BV develops and commercializes cardiovascular biomarkers. The firm offers miRNA profiling services. It engages in the discovery, validation, and commercialization of biomarkers that improve diagnosis, prognosis and management of cardiac diseases. The company was founded in 2007 by Mat J. A. P. Daemen, Yigal M. Pinto and Tilman Hackeng and is headquartered in Maastricht, the Netherlands.

United Telecom NV develops software technologies for mobile operators. It provides fixed and mobile telephony and VDSL products. The company was founded in 1990 and is headquartered in Rotselaar, Belgium.

FABPulous BV develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability. It offers ultra rapid plasma preparation platform that can make a defined dilution of plasma from a small volume of whole blood in seconds and integrated lateral flow IVD platform. The company’s tests provide diagnosis and benefit to the patient, as well as the healthcare sector, the insurance industry, governments and society in general. FABPulous was founded in 2008 and is headquartered in Maastricht, the Netherlands.

SomantiX BV develops imaging and therapy of cancer through targeting of tumor blood vessels. The firm offers Somantix’ screening platform which is in combination with the binder generation technologies that allows validation of new therapeutic targets and development of new cancer medicines. The company was founded in 2008 and is headquartered in Utrecht, Netherlands.

Brightlands Venture Partners is an independent regional venture capital firm headquartered in Brightlands, Netherlands. The firm was founded in 2004.

Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands.

Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom.

DROIA NV (DROIA) is an Independent Venture Capital firm founded in 2011 by Bart van Hooland. The firm is headquartered in Meise with additional office in Luxembourg.

Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland.

Blue Ocean Robotics ApS develops and introduces market-ready robots for industry, healthcare, education, agriculture and construction. The company was founded by Claus Risager and is headquartered in Odense, Denmark.

Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom.

Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom.

OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands.

Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain.

Convert Pharmaceuticals SA provides preclinical stage drug development services. Its product hypoxia activated prodrug (HAP) is a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. The company was founded by Philippe Lambin, Nicolas Geuens, and Paul Tulcinsky on February 24, 2017 and is headquartered in Liege, Belgium.

Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark.

Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.

Black Belt Therapeutics Ltd. is a British biotechnology company.

Neuroplast BV is a Dutch stem cell technology company that focuses on developing autologous cell products for the treatment of primarily inflammation-driven neurological disorders. Neuroplast is located in Brightlands Chemelot Campus in the Netherlands. The company's transformative treatment, Neuro-cellsò, is currently being tested for traumatic spinal cord injury (TSCI) and aims to reduce the irreversible impact of TSCI during the crucial first phase. The company was founded in August 2014 by physician De Munter and neurologist Erik Wolters, and current investors include Invest, Brightlands Venture Partners, and Liof NV. Johannes de Munter has been the CEO of the company since 2016.

DF II LP NV is a private company based in Meise, Belgium. The Belgian company was founded in 2018.